中國醫藥大學機構典藏 China Medical University Repository, Taiwan:Item 310903500/30623
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 29490/55136 (53%)
造访人次 : 1521268      在线人数 : 212
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻
    主页登入上传说明关于CMUR管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30623


    题名: Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma
    作者: Yang, MD;Wu, CC;Chiou, SH;Chiu, CF;Lin, TY;Chiang, IP;Chow, KC
    贡献者: 附設醫院醫研部;China Med Coll Hosp, Dept Med Res, Taichung 404, Taiwan;China Med Coll Hosp, Dept Surg, Taichung 404, Taiwan;China Med Coll Hosp, Dept Internal Med, Taichung 404, Taiwan;China Med Coll Hosp, Dept Pathol, Taichung 404, Taiwan;China Med Coll, Inst Med Sci, Taichung, Taiwan;Taichung Vet Gen Hosp, Div Gen Surg, Taichung, Taiwan;Natl Chung Hsing Univ, Grad Inst Vet Microbiol, Taichung 40227, Taiwan
    日期: 2003
    上传时间: 2010-09-24 14:58:52 (UTC+8)
    出版者: PROFESSOR D A SPANDIDOS
    摘要: Purpose : Nasopharyngeal carcinoma (NPC) is a radiosensitive and chemosensitive tumor. This randomized phase III trial compared concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in patients with advanced NPC. Patients and Methods: From December 1993 to April 1999, 284 patients with 1992 American Joint Committee on Cancer stage III to IV (MO) NPC were randomly allocated into two arms. Similar dosage and fractionation of RT was administered in both arms. The investigational arm received two cycles of concurrent chemotherapy wit h cisplatin 20 Mg/m(2)/d plus fluorouracil 400 Mg/m(2)/d by 96-hour continuous infusion during the weeks 1 and 5 of RT. Survival analysis was estimated by the Kaplan-Meier method and compared by the log-rank test. Results: Baseline patient characteristics were comparable in both arms. After a median follow-up of 65 months, 26.2% (37 of 141) and 46.2% (66 of 143) of patients developed tumor relapse in the CCRT and RT-alone groups, respectively. The 5-year overall survival rates were 72.3% for the CCRT arm and 54.2% for the RT-only arm (P =.0022). The 5-year progression-free survival rates were 71.6% for the CCRT group compared with 53.00% for the RT-only group (P =.0012). Although significantly more toixicity was noted in the CCRT arm, including leukopenia and emesis, compliance with the combined treatment was good. The second cycle of concurrent chemotherapy was refused by nine patients and was delayed for a I week for another nine patients. There were no treatment-related deaths in either arm. Conclusion: We conclude that CCRT is superior to RT alone for patients with advanced NPC in endemic areas.
    關聯: ONCOLOGY REPORTS 10(2):271-276
    显示于类别:[台中附設醫院] 期刊論文

    文件中的档案:

    没有与此文件相关的档案.



    在CMUR中所有的数据项都受到原著作权保护.

    TAIR相关文章

     


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈